低剂量阿司匹林新使用者上消化道与下消化道出血的发生率
基于英国健康改善网络2000—2012年数据,纳入199,079例低剂量阿司匹林新使用者(中位年龄64.0岁),随访中位5.4年(最长14年),估算上消化道出血粗发生率为0.97/1000人年(95%CI 0.91-1.02),下消化道出血为1.68/1000人年(95%CI 1.60-1.75);下消化道出血发生率高于上消化道出血,但下消化道出血的住院率和30天死亡率更低。
要点
- 低剂量阿司匹林新使用者下消化道出血发生率高于上消化道出血(1.68 vs 0.97/1000人年)。
- 上消化道出血者58.9%需住院,下消化道出血者72.8%转诊二级医疗。
- 住院上消化道出血发生率0.57/1000人年 vs 下消化道0.45/1000人年。
核心结论
- 在低剂量阿司匹林使用者中,下消化道出血发生率高于上消化道出血,但住院率和30天死亡率上消化道更高,下消化道更低。
- 这些估计值对低剂量阿司匹林用于心血管和结直肠癌预防的风险-获益评估有价值。
研究设计与样本
- 基于英国健康改善网络初级保健数据库(2000—2012年)的人群研究,纳入199,079例低剂量阿司匹林新使用者,中位年龄64.0岁,随访中位5.4年(最长14年)。
- 随访识别上消化道出血和下消化道出血新发病例,经多步验证后计算总体及年龄、性别别发生率,并分析医疗使用和出血后30天内死亡。
- 同时估计匹配(1:1)的非低剂量阿司匹林使用者队列的发生率。
主要发现
- 低剂量阿司匹林使用者发生上消化道出血1115例、下消化道出血1936例;上消化道出血者58.9%住院,下消化道出血者72.8%转诊二级医疗。
- 粗发生率每1000人年:上消化道出血0.97(95%CI 0.91-1.02),下消化道出血1.68(95%CI 1.60-1.75)。
- 住院上消化道出血0.57(95%CI 0.53-0.61)/1000人年 vs 住院下消化道出血0.45(95%CI 0.42-0.49)/1000人年;转诊未住院上消化道出血0.39(95%CI 0.36-0.43)/1000人年 vs 下消化道出血1.22(95%CI 1.16-1.29)/1000人年。
- 致死性上消化道出血0.06(95%CI 0.04-0.07)/1000人年,致死性下消化道出血0.01(95%CI 0.01-0.02)/1000人年;非致死性上消化道出血0.91(95%CI 0.86-0.97)/1000人年,非致死性下消化道出血1.66(95%CI 1.59-1.74)/1000人年。
- 非低剂量阿司匹林使用者上消化道出血0.67(95%CI 0.63-0.75)/1000人年,下消化道出血0.76(95%CI 0.72-0.82)/1000人年。
临床怎么用
- 原文未据此给出推荐,仅指出这些估计值对低剂量阿司匹林用于心血管和结直肠癌预防的风险-获益评估有价值。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: There are few data on the incidence of upper and lower gastrointestinal bleeding (UGIB and LGIB) from observational studies of low-dose aspirin users. We aimed to estimate incidence rates of UGIB and LGIB in a large cohort of new users of low-dose aspirin in the United Kingdom, with subanalyses of hospitalization status and fatalities. METHODS: We performed a population-based study of 199,079 new users of low-dose aspirin (median age, 64.0 years) identified from the Health Improvement Network primary care database (2000-2012). Individuals were followed for a median 5.4 years (maximum, 14 years) to identify new cases of UGIB and LGIB. Following multistep validation, we calculated overall and age- and sex-specific incidence rates; we performed subanalyses for health care use and death within 30 days of GIB. We also estimated rates within a matched (1:1) cohort of nonusers of low-dose aspirin at the start of the follow-up period. RESULTS: The low-dose aspirin users had 1115 UGIB events and 1936 LGIB events; most subjects with UGIB events (58.9%) were hospitalized, whereas most subjects with LGIB events were referred to secondary care (72.8%). Crude incidence rates of GIB per 1000 person-years were 0.97 for subjects with UGIB (95% CI, 0.91-1.02) and 1.68 for subjects with LGIB (95% CI, 1.60-1.75). Incidence rates per 1000 person-years for patients hospitalized for GIB were 0.57 for UGIB (95% CI, 0.53-0.61) and 0.45 for LGIB (95% CI, 0.42-0.49); for referred (but not hospitalized) cases, these values were 0.39 for UGIB (95% CI, 0.36-0.43) and 1.22 for LGIB (1.16-1.29). Incidence rates per 1000 person-years were 0.06 for fatal UGIB (95% CI, 0.04-0.07), 0.01 for fatal LGIB (95% CI, 0.01-0.02), 0.91 for nonfatal UGIB (95% CI, 0.86-0.97), and 1.66 for nonfatal LGIB (95% CI, 1.59-1.74). Among nonusers of low-dose aspirin, incidence rates per 1000 person-years were 0.67 (95% CI, 0.63-0.75) for UGIB and 0.76 (95% CI, 0.72-0.82) for LGIB. CONCLUSION: In a population-based study of low-dose aspirin users, the incidence of LGIB was higher than the incidence of UGIB. However, incidence rates of hospitalized GI bleeds and 30-day mortality rates were lower for LGIB than for UGIB. These estimates are valuable for benefit-risk assessments of low-dose aspirin for cardiovascular and colorectal cancer prevention.
引用
- Cea Soriano L, Lanas A, Soriano-Gabarró M, et al. Incidence of Upper and Lower Gastrointestinal Bleeding in New Users of Low-Dose Aspirin. Clin Gastroenterol Hepatol. 2018. PMID: 29908361. doi:10.1016/j.cgh.2018.05.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。